AMRA Medical

As 2024 wraps up, we would like to say thank you to our AMRA friends, customers, and collaborators. Thank you for your continued support and partnership! This year has been a thrilling journey of innovation and progress, and we can’t wait to achieve even more together in the year ahead! Wishing you all a joyful holiday season and a New Year filled with success, health, and new breakthroughs. 🌟 #HappyHolidays #NewYear2025 #AMRAMedical

Are you our new team member? We are looking for a new colleague to join our science team, with a focus on the cardiometabolic and obesity area. You will support a wide range of research studies including pharmaceutical clinical trials and academic research. With the rising market for anti-obesity medications, this role will be central in supporting studies investigating changes in fat distribution and muscle composition with significant weight reduction. AMRA has a strong scientific foundation and presence, leading to possibilities of being involved in research studies as a co-researcher/author in both internal and external scientific projects. Read more about this opportunity here: https://lnkd.in/gC2c734U #ClinicalScientist #AMRAMedical #JobOpportunity #ClinicalResearch #ClinicalTrials #MRI #PrecisionMedicine

Catch Up With AMRA @ the 2024 Innovation in Obesity Therapeutics Summit! Are you in sunny California for the 2024 Innovation in Obesity Therapeutics Summit? AMRA wants to connect with you in San Diego! The Summit, which is part of an annual three-event series also comprised of the GLP-1-Based Therapeutics Summit, as well as the Obesity and Weight Loss Drug Development Summit, aims to bring together the obesity landscape’s most notable and influential industry players to share the latest on therapeutic development for weight loss. AMRA is proud to share that we are a 2024 Summit Expertise Partner, helping to make this event a success in conjunction with the Summit and our industry collaborators. In this new era of weight-loss drug development, where advancements are rapid and the landscape is ever-changing, AMRA is committed to being at the forefront of the field, by helping to develop MRI-based methodologies that propel drug research forward beyond standard measures of weight loss. Opportunities to move weight-loss drug research forward through knowledge exchange at conferences such as this one are ones that AMRA is excited to take! Make sure to catch our CEO, Dr. Olof Dahlqvist Leinhard, at his seminar on December 11th, at 09.00 AM where he will share more about how AMRA is transforming treatment differentiation in weight loss trials. Interested to learn more about AMRA’s perspective on weight loss and its impact on obesity? View our latest thought piece: https://lnkd.in/d7kw7Q_n Reach out to info@amramedical.com if you want to get in touch and meet with the team at the Summit, or to learn more about how our unique fat and muscle body composition assessments are transforming disease research in obesity and beyond. #Beyondweightloss #AMRAMedical #MRI #obesity #metabolicdisease #clinicaltrials #GLP1s #precisionmedicine #weightloss

AMRA @ the Global CVCT Forum 2024! 🌎 AMRA is taking part in The Global CardioVascular Clinical Trialists (CVCT) Workshop, happening December 9-11 at The Mayflower Hotel in Washington, DC! This exclusive workshop unites top cardiovascular investigators, pharmaceutical R&D leaders, and regulators to shape the future of cardiovascular research. With over 400 speakers across 40 sessions, including leading cardiologists and key figures from academia, industry, and regulatory bodies, this is the premier forum for advancing cardiovascular drug, device, and biomarker development. We at AMRA are honored to contribute to this year’s discussions! On December 11, during the session ‘Anti-obesity medicines and CV outcomes trials part 2 - How ongoing and future trials are adapting to the new landscape’, AMRA´s Dr. Jennifer Linge will present “How to measure and what are the consequences of muscle loss relative to fat loss? Reach out to info@amramedical.com if you want to learn more about how our unique fat and muscle composition assessments are transforming research in cardiovascular disease and beyond. #CVCT2024 #AMRAMedical #MRI #CardiovascularResearch #ClinicalTrials #GLP1 #obesity #TypeIIDiabetes #precisionmedicine #pharma

How can MRI-based muscle mass and myosteatosis measurements redefine sarcopenia assessment and clinical trials? At the #SCWDConference2024 keynote session, Olof Dahlqvist Leinhard explores these critical biomarkers and their impact on outcomes and function. Don’t miss this opportunity to gain valuable insights! AMRA Medical December 6, 2024 12:00–12:45 PM EST | Metropolitan Ballroom #Sarcopenia #Cachexia #Musclewasting #MRI #ClinicalTrials #AMRA

-Don’t Miss AMRA Medical @ SCWD 2024 in Washington, DC!- On December 6-8th, AMRA is excited to contribute to the vibrant discussions at the 17th Annual International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD 2024) Conference in Washington, DC! During this jam-packed weekend, leaders across academia, industry, and the clinic will get together and share the latest in cutting-edge research and care in sarcopenia and muscle wasting disorders. AMRA is honored to be a part of multiple discussions and sessions throughout the duration of the event, bringing the latest developments on the use of MRI-based muscle composition analysis for research in sarcopenia and related wasting disorders to the forefront of the field: Poster Sessions 🗓 Dec 6 | 15:50–16:40 //  Dec 7 | 10:20–11:10 & 14:30–15:10 🔬 “Associations of low lean mass by EWGSOP2, FNIH, and EASO/ESPEN with all-cause mortality across BMI classes” 🥼 Presented by: Dr. Jennifer Linge SCWD Chairing Session 🗓 Dec 6 | 16:45–18:00 📍 Session G - General Sarcopenia 🔬 “Body composition changes induced by GLP-1 RAs in obesity therapy” 🎤🥼 Co-chaired by our own Dr. Jennifer Linge! SCWD “Rapid-Fire Presentation” 🗓 Dec 7 | 15:05–15:55 🔬”Associations of low lean mass by EWGSOP2, FNIH, and EASO/ESPEN with all-cause mortality across BMI classes” 🥼Dr. Jennifer Linge Spotlight: AMRA Keynote Lecture 🗓 Dec 6 | 12:00-12:45 📍 Metropolitan Ballroom 🔬MRI-based quantification of muscle mass and myosteatosis as biomarkers for clinical trials and sarcopenia assessment 🥼Dr. Olof Dahlqvist Leinhard If you’re attending SCWD 2024, make sure not to miss us at our booth in DC! We’re eager to connect with you at the conference. If you can’t make it to SCWD 2024 this year, reach out to info@amramedical.com and we can help you learn more about how our unique fat and muscle body composition assessments are transforming disease research in sarcopenia and beyond. We can’t wait to see you at SCWD 2024! #AMRAMedical #ClinicalTrials #SCWD2024 #Sarcopenia #MuscleComposition #WeightLoss #obesity #Beyondweightloss #metabolicdisease #GLP1s #precisionmedicine #MRI

AMRA Contributes to Regulatory Workshop Ahead of SCWD 2024 As the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) gears up for their 17th annual international conference in Washington, DC early next month, AMRA is pleased to share that our own Dr. Jennifer Linge will be presenting during a regulatory workshop ahead of SCWD 2024 on December 6th! The invitation-only workshop, which is hosted by SCWD and includes stakeholders from industry and regulatory agencies such as the FDA, will foster conversation around muscle wasting in weight loss therapy, with AMRA presenting on the various challenges associated with analyzing body composition to understand incretin-based therapies and muscle loss. AMRA is proud to be given a seat at the table and is looking forward to exchanging crucial knowledge with other leaders in the field that will help move disease research in this area forward. Reach out to info@amramedical.com if you want to learn more about how our unique fat and muscle composition assessments are transforming research in sarcopenia and beyond. Stay tuned for more about AMRA’s presence at #SCWD2024, and make sure to connect with the team in DC this December if you’re attending the conference. We hope to see you there! #AMRAMedical #ClinicalTrials #SCWD2024 #Sarcopenia #MuscleComposition #WeightLoss #obesity #Beyondweightloss #metabolicdisease #GLP1s #precisionmedicine #MRI

A big thank you to our friends and collaborators at the Karolinska Institutet for working with AMRA on this important research piece! Read more about the paper, titled “Longitudinal changes in regional fat and muscle composition and cardiometabolic biomarkers over 5 years of hormone therapy in transgender individuals” here: https://lnkd.in/djRvc66U. You can check out the full manuscript here: https://lnkd.in/d57C-eDf #AMRAMedical #MRI #BodyComposition #MuscleVolume #FatDistribution #HormoneTherapy #Science

AMRA to Headline With Seminar at 2024 Innovation in Obesity Therapeutics Summit This December 10-12, the West Coast Innovation in Obesity Therapeutics Summit will be taking place in sunny San Diego, California! AMRA is excited to share that we are a 2024 Summit Expertise Partner, helping to make this event a success in conjunction with the Summit and our industry collaborators. Our CEO, Dr. Olof Dahlqvist Leinhard, will be headlining a seminar centered around the use of novel MRI-based body composition approaches, notably AMRA’s unique fat distribution and muscle volume z-score biomarkers, to transform treatment differentiation methods beyond simple weight loss comparisons in obesity trials. Dr. Leinhard will take attendees on a journey through the advent of the z-score methodologies via robust AMRA-led studies, as well as their utility in exploring varying effects of the GLP-1 agonists liraglutide and tirzepatide on muscle and fat measurements in recent trials. Stay tuned for more about AMRA @ the 2024 Innovation in Obesity Therapeutics Summit, and make sure to connect with the team in San Diego. If you’re attending the conference - we want to meet you there! Reach out to info@amramedical.com to get in touch with the team ahead of the Summit, or to learn more about how our unique fat and muscle body composition assessments are transforming disease research in obesity and beyond. 🕛NOTE UPDATED TIME: 09.00 AM 🗓December 11, 2024  🔬”MRI-based Body Composition Reimagined: Building a New Foundation for Treatment Differentiation Beyond Weight Loss” 🥼Olof Dahlqvist Leinhard, PhD #Beyondweightloss #AMRAMedical #obesity #metabolicdisease #clinicaltrials #GLP1s #precisionmedicine #weightloss #MRI

AMRA To Share Baseline Results from ACCESS-ESLD @ AASLD’s The Liver Meeting 2024 If you’re in San Diego this week for the 75th annual AASLD’s The Liver Meeting (TLM), make sure to check out AMRA’s poster (#4137) today November 18 @ 1PM - where our own Dr. Mikael Forsgren will be sharing baseline results from the important ACCESS-ESLD study! ACCESS-ESLD is a Swedish multi-center study led by Linköping University that includes 150 adult patients with liver cirrhosis undergoing hepatocellular carcinoma surveillance. Over a duration of 2 years, patients will be assessed every 6 months with a comprehensive clinical examination and a whole-body MRI examination. The study shows that adverse muscle composition, the combination of low muscle volume and high muscle fat, is a highly prevalent phenotype (20%) in this patient group. This population presented with higher frailty, poorer physical performance, and worse health status regardless of muscle volume, underscoring the importance of considering muscle fat alongside muscle volume to identify vulnerable sarcopenic patient groups within liver disease. The study investigators hope that the findings of ACCESS-ESLD will continue the shift in management of liver disease towards employing more of a preemptive approach, by developing ways to monitor disease progression and severity while also identifying patients at risk for major adverse events or mortality. AMRA’s significant involvement in a hallmark study in the liver disease space such as this one embodies the company’s commitment to advancing both research and clinical care. Come find us at TLM 2024 to learn more about AMRA Medical and how the use of MRI-based body composition analysis is advancing disease research in liver disease and beyond! #AMRAMedical #TLM24 #TLMdX #LiU #ACCESSESLD #liverdisease #cirrhosis #clinicaltrials #precisionmedicine #MRI